GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology

On November 27, 2025 GC Genome, a leading clinical genomics and liquid biopsy company, reported that its collaborative study with Professor Byeon, Jeong-Sik’s team at Asan Medical Center has been published in The American Journal of Gastroenterology(AJG).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GC Genome applied its proprietary AI-based fragmentomics technology, used in its MCED test, ai-CANCERCH. This study demonstrates the potential for a convenient, alternative to colonoscopy and fecal based screening methods, while enabling early detection of colorectal cancer and advanced adenomas.

Study Overview

A total of 1,677 individuals were enrolled, including: 302 with CRC, 108 with AA
1,267 with normal colonoscopy as healthy or non-cancer controls
The test analyzes cfDNA fragmentomic signatures using low-coverage whole-genome sequencing (Lc-WGS) combined with a proprietary AI algorithm, enabling highly sensitive detection of early-stage disease.

Key Findings

CRC sensitivity: 90.4%
Specificity in individuals with normal colonoscopy: 94.7%
Sensitivities by CRC stage : 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV)
Sensitivity for T1N0 lesions (eligible for endoscopic resection): 90.0%
Sensitivity for AA: 58.3%
The results remained consistent regardless of: CRC locations (left vs. right colon), age of CRC patients(<60 vs. ≥60), and AA locations

These findings highlight the test’s potential as a reliable cfDNA-based blood test for CRC screening and early prevention.

A GC Genome spokes person stated "Detecting colorectal cancer together with precancerous lesions represents a meaningful advance in prevention. With our fragmentomics technology now validated through publication in a leading gastroenterology journal, GC Genome will continue expanding global clinical collaborations and screening applications."

(Press release, GC Genome, NOV 27, 2025, View Source [SID1234660991])